The expansion of the strategic partnership reinforces the solid foundation of the collaborative efforts that commenced in April 2024 The collaboration supports Teva's Pivot to Growth strategy and adds to the company's biosimilar portfolio Both companies reaffirm their shared commitment to making high-quality, affordable treatments accessible to patients worldwide TEL AVIV, ISRAEL and MADRID, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Indust ...

This first-to-market launch showcases Teva's proven strengths in complex generic formulations and enhances Teva's strategic goal of sustaining a generic powerhouse. Octreotide acetate for injectable suspension is indicated to treat acromegaly and severe diarrhea for carcinoid syndrome. PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of the first and only generic version of Sand ...

TEL AVIV, Israel, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its financial results for the third quarter of 2024 on Wednesday, November 6, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webca ...

文章核心观点 - 欧洲RIM-TD开放标签延长(OLE)研究显示,在为期三年的研究中,使用重氢四苯氮芥治疗的患者,其难治性运动障碍(TD)症状得到长期改善[1][2] - 重氢四苯氮芥已在ARM-TD、AIM-TD和RIM-TD三项研究中均证实能为TD患者提供快速、持续和临床意义上的运动功能改善[1][2][6][7] - 重氢四苯氮芥已在美国和其他一些市场获批上市[8] 行业概况 - TD是一种严重的慢性运动障碍,影响15%-25%服用某些抗精神病药物的患者,表现为面部、躯干和/或其他身体部位的不自主、异常和重复性运动[3][4] - 目前欧洲治疗TD的方法证据不足,减量、停用或转换抗精神病药物治疗很难逆转TD,这可能导致基础疾病管理不佳,复发风险增加[4] 公司概况 - 特维制药是一家全球领先的制药公司,拥有多样化的产品组合,利用其仿制药专长并提高创新能力,持续推动现代医药的发现、交付和扩展发展[6] - 特维制药拥有37,000名员工,遍布58个市场,致力于推动科学创新的边界,提供优质药品,改善全球数百万患者的健康状况[6]

As a leader in neuroscience, Teva is committed to researching new treatment innovations that may help address unmet needs in treating schizophrenia, including TEV-'749 Currently, there is no long-acting olanzapine treatment option available for the treatment of schizophrenia that does not contain a boxed warning for Post-Injection Delirium/Sedation Syndrome (PDSS) New Phase 3 SOLARIS and Phase 1 safety data show no incidence of PDSS in study participants receiving TEV-'749 to date TEL AVIV, Israel & PARSIPP ...

文章核心观点 - 公司致力于通过科学和临床进展来帮助解决精神分裂症治疗的未满足需求,为患者和医疗保健专业人员提供最佳治疗选择和决策 [1][2][3] - 新数据显示,在停用每月一次的RBP-7000后4周内切换到UZEDY可提供最可比的药代动力学(PK)特征,并确定了可比的剂量 [3] - 新的ADVANCE调查结果突出了患者接受长效注射治疗的主要原因,包括症状/病情改善、医生建议以及使用便利性 [4][5] 行业概况 - 精神分裂症是一种复杂的医疗状况,患者可能需要在口服药物或不同长效注射剂之间进行切换 [2] - 精神分裂症患者约80%在最初5年内经历多次复发,每次复发都会带来生物学风险,如功能丧失、治疗难治性和大脑形态学变化 [6] - 患者常常不了解自己的疾病及其后果,这导致治疗依从性差、高中断率,从而造成大量直接和间接的医疗费用 [6] 公司产品 - UZEDY是一种用于治疗成人精神分裂症的长效注射剂,可每1个月或2个月给药一次 [7][8] - 在临床试验中,UZEDY显著降低了精神分裂症复发的风险 [7] - UZEDY采用许可自MedinCell的共聚物技术,可在皮下注射后实现吸收和持续释放 [7]

Teva Pharmaceuticals Industries Limited (NYSE:TEVA) Bank of America Global Healthcare Conference September 18, 2024 3:15 AM ET Company Participants Richard Francis - President & CEO Conference Call Participants Jason Gerberry - BofA Securities Jason Gerberry Thank you, Richard, for joining us here at the BofA Global Healthcare Conference in London. My name is Jason Gerberry. I'm one of the SMID cap biotech and specialty pharma analysts. And so pleased to be introducing our next company presenter, Teva Pharm ...

会议主要讨论的核心内容 - 公司在过去20个月内制定了明确的"转向增长"战略,通过最大化创新产品组合和保持强大的仿制药业务来推动公司增长[3][4] - 公司正在重新定义自己,从一家全球仿制药公司转变为一家拥有世界级仿制药业务和快速增长的创新业务的全球制药公司[4] - 公司正在努力实现2027年的财务目标:收入5%复合年增长率、30%的营业利润率和2倍的净债务/EBITDA比率[6][7] - 公司正在通过资产剥离、偿还债务、投资增长动力和业务发展来实现投资级评级[7][8] 问答环节重要的提问和回答 - 分析师询问公司何时能够实现投资级评级,公司表示无论是否有资产剥离,都将在2027年之前实现该目标[5][6][7] - 分析师询问公司在业务发展方面的计划,公司表示将优先考虑内部增长机会,同时也在积极评估外部机会,但要确保与公司的"转向增长"战略相符[9][10] - 分析师询问公司的长效注射剂产品组合,包括UZEDY和即将上市的奥氮平长效注射剂,公司表示对这些产品的商业前景充满信心,并将充分利用现有的销售和营销基础[13][14][15] - 分析师询问公司的TL1A和IL-15等创新管线,公司表示这些资产具有多适应症的潜力,是公司创新管线的重要组成部分[57][58][63] - 分析师询问公司的ICS/SABA复合制剂,公司表示尽管AstraZeneca先行进入市场,但公司的产品差异化和在呼吸系统领域的经验将有助于公司在该领域取得成功[65][66][67]

Teva Pharmaceutical Industries Limited's (TEVA) stock has risen 72.5% so far this year compared with an increase of 17.9% for the industry. The stock has also outperformed the sector and the S&P 500, as seen in the chart below. TEVA Stock Outperforms Industry, Sector & S&P 500 Zacks Investment Research Image Source: The stock has also been consistently trading above 200-day moving averages since mid-November 2023. In fact, Teva's stock price is showing improvement after years of remaining suppressed. Teva i ...

JHVEPhoto Israel-based Teva Pharmaceutical Industries Limited (NYSE:TEVA), which develops both generic and branded drugs, looks poised to benefit from multiple, significant, positive catalysts over the medium term and long term. One of these drivers is the increasing demand for generic drugs due to a favorable macro and political environment for these products. Moreover, the demand for Teva's own generic and branded drugs is rising a great deal, and chances are high that the latter trends will continue goin ...